Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?

Expert Rev Clin Pharmacol. 2023 Apr;16(4):275-278. doi: 10.1080/17512433.2023.2193683. Epub 2023 Mar 21.

Authors

Gabriella Guo Sciriha¹, Janet Sultana², Joseph Borg³

Affiliations

¹ Department of Ophthalmology, Mater Dei Hospital, Msida, Malta.
² Exeter College of Medicine and Health, University of Exeter, Exeter, UK.
³ Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta, Msida, Malta.

PMID: 36945753
DOI: 10.1080/17512433.2023.2193683

No abstract available

Keywords: Corneal dystrophy; drug repurposing; orphan drugs; rare disease; transforming growth factor beta induced.

Publication types

Editorial
Comment

MeSH terms

Corneal Dystrophies, Hereditary* / metabolism
Corneal Dystrophies, Hereditary* / therapy
Humans
Mutation
Transforming Growth Factor beta* / genetics
Transforming Growth Factor beta* / metabolism

Substances

Transforming Growth Factor beta